HARTMANN SCIENCE CENTER

C. parapsilosis is now considered one of the most common causes of systemic Candida infections. While the pathogen was previously associated with infections in children, it is now frequently detected in catheter-related bloodstream infections (sepsis) in adults [1]. Infections of the heart (endocarditis), the central nervous system, the eyes, bones, and internal organs are also possible [2,3].
The mortality rate for invasive infections with C. parapsilosis is high and, according to the World Health Organization (WHO), ranges between 20% and 45% despite fungicidal treatment [3].
Due to the increasing threat of resistant fungi, the WHO published a list of fungi that pose a health risk (Fungal Priority Pathogen List, FFPL) for the first time in 2022, in which C. parapsilosis is listed in the high priority group (second highest priority group). The list contains a total of 19 fungi, of which four (Cryptococcus neoformans, Candida auris, Aspergillus fumigatus, and Candida albicans) belong to the highest priority group (critical priority) [3]. Overall, the WHO assesses the antifungal resistance of C. parapsilosisas moderate, with resistance to azoles playing a particularly important role [3].
A retrospective epidemiological study published in 2025 suggests that azole-resistant C. parapsilosis is also increasingly spreading in healthcare facilities in Germany [1].
Hand and surface disinfectants must have yeasticidal efficacy.
Here you can find products with a yeasticidal spectrum of activity.